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Background: Herring roe is an underutilized source of n-3 polyunsaturated fatty acids (PUFAs) for human
consumption with high phospholipid (PL) content. Studies have shown that PL may improve bioavailability of n-3
PUFAs. Arctic Nutrition’s herring roe product MOPL™30 is a PL: docosahexaenoic acid (DHA)-rich fish oil mixture,
with a DHA:eicosapentaenoic acid (EPA) ratio of about 3:1, which is also rich in choline. In this pilot study, we determined
if MOPL30 could favorably affect plasma lipid parameters and glucose tolerance in healthy young adults.
Methods: Twenty female and one male adults, between 22 and 26 years of age, participated in the study. Participants
took encapsulated MOPL30, 2.4 g/d EPA + DHA, for 14 days, and completed a three-day weighed food record before
and during the capsule intake. Plasma lipids and their fatty acid (FA) composition, plasma and red blood cell (RBC)
phosphatidylcholine (PC) FA composition, acylcarnitines, choline, betaine and insulin were measured before and after
supplementation (n = 21), and one and four weeks after discontinuation of supplementation (n = 14). An oral glucose
tolerance test was performed before and after supplementation.
Results: Fasting plasma triacylglycerol and non-esterified fatty acids decreased and HDL-cholesterol increased after 14 days
of MOPL30 intake (p < 0.05). The dietary records showed that PUFA intake prior to and during capsule intake was not
different. Fasting plasma glucose was unchanged from before to after supplementation. However, during oral glucose
tolerance testing, blood glucose at both 10 and 120 min was significantly lower after supplementation with MOPL30
compared to baseline measurements. Plasma free choline and betaine were increased, and the n-6/n-3 polyunsaturated
(PUFA) ratio in plasma and RBC PC were decreased post-supplementation. Four weeks after discontinuation of MOPL30,
most parameters had returned to baseline, but a delayed effect was observed on n-6 PUFAs.
Conclusions: Herring roe rich in PL improved the plasma lipid profile and glycemic control in young adults with an
overall healthy lifestyle.
Keywords: Herring roe, Phospholipids, Eicosapentaenoic acid, Docosahexaenoic acid, Omega-3 polyunsaturated fatty
acids, Glycemic control, Choline, AcylcarnitinesBackground
The health benefits of a higher fish intake, thereby increas-
ing the intake of n-3 long-chain polyunsaturated fatty acids
(PUFAs) and reducing the n-6 PUFA/n-3 PUFA ratio, has
been documented in several studies [1]. Cardioprotective
effects of n-3 PUFAs, in particular eicosapentaenoic acid* Correspondence: bodil.bjorndal@k2.uib.no
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uted to reduction in fasting triacylglycerol (TAG), blood
pressure lowering, anti-inflammatory and antiarrhythmic
effects, improved insulin sensitivity and vascular endothelial
function, and reduced thrombotic tendency [2]. The effi-
cacy of n-3 PUFAs in the prevention of heart disease has
been challenged in recent meta-studies, but it is important
to note that newer studies could be hampered by a higher
general intake of n-3 PUFAs and improved treatment pro-
tocols for heart patients [3]. The current recommendedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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http://www.lipidworld.com/content/13/1/82intake is 250 mg/day EPA + DHA for the general popula-
tion, and 300 mg/day for pregnant women (European Food
Safety Authority (EFSA)). The American Heart Association
(AHA) recommends 1 g/day EPA + DHA for patients with
cardiovascular disease (CVD). Combined with the increased
focus on n-3 PUFA intake in the media, this has led to a
large n-3 PUFA supplement market dominated by fish oil
from sardines. However, the need for new sources of high-
quality EPA and DHA is increasing.
Immature roe from spring-spawning Norwegian herring
is an underutilized source of n-3 PUFA-rich phospholipids
(PLs). Of the approximately 600,000-ton herring caught in
Norway each year, only a small percentage of herring roe
is used for human consumption. The product MOPL30
(Arctic Nutrition) from herring roe contains about 45% n-
3 PUFA (mg/g product basis), with a DHA:EPA ratio of
approximately 3:1. In addition, 30% of the lipids are PL of
which most (75%) in the form of phosphatidylcholine
(PC). Thus herring roe provides choline, an important nu-
trient involved in many biochemical pathways.
The bioactivity of n-3 PUFAs may be influenced by the
lipid structures in which they are incorporated. PLs and
free fatty acids have increased bioavailability compared to
TAG and ethyl ester forms of n-3 PUFAs, respectively
[4,5]. PL from krill have been shown to influence gene ex-
pression more than TAG from fish oil in mice, at a similar
dose of EPA and DHA [6]. In particular, genes involved in
glucose and lipid metabolism were more affected by PL
than TAG [6,7]. A recent study comparing the bioavail-
ability of PL and TAG in the form of krill oil and fish oil
in healthy subjects demonstrated increased levels of EPA
and DHA in plasma and red blood cells (RBC) after four
weeks of krill oil intake compared to fish oil [8]. In
addition, animal studies have shown a more efficient re-
duction in plasma lipid levels with PL compared to TAG
intervention [9]. Herring roe oil supplementation has
shown promising results in animal studies, including re-
duction in plasma lipids and inflammatory parameters,
and improved insulin sensitivity [10,11].
The aim of this study was to determine the effect of n-3
PUFA when given in PL-rich herring roe on blood lipids
and glucose tolerance in healthy subjects with a balanced
diet, and to determine uptake of n-3 PUFAs into red blood
cells as a measure of bioavailability. Follow-up samples
were included to determine how long the n-3 PUFA
remained in circulation after discontinuation of supple-
mentation (washout effects).
Results
Characteristics of the study population
The study included twenty-one young, healthy individuals
aged 20 to 26 years, with a mean ± SD body mass index of
21.2 ± 2.8, and range between 15.1 and 26.7. Fourteen of
the participants completed a three day weighed foodrecord during the two weeks prior to supplementation, and
again during the two weeks intervention. The energy %
from PUFA in the habitual diet was (mean ± SD) 7.5 ± 2.8
before and 6.7 ± 2.0 during the intervention (p = 0.264, n =
14), indicating that the dietary intake of PUFA remained
unchanged during the study period. Furthermore, there
was no change in dietary intake of total fat, saturated fatty
acids (FA), monounsaturated FA, protein or carbohydrate
(data not shown).
The capsules were taken during a meal, and there were
no reports of reflux or unpleasant taste following capsule
intake.
MOPL30 supplementation affected plasma lipid levels
Plasma lipid levels were measured at baseline (start) and
after (end) two weeks of MOPL30 supplementation. In
addition, washout (WO) samples were taken one and four
weeks after the final day of capsule intake. The TAG level
was significantly reduced in the end samples (21% reduc-
tion). However, the reduction at WO week one (p = 0.10)
and four (p = 0.30) compared to start was not significant
(Figure 1a). Non-esterified FAs (NEFAs) were also signifi-
cantly reduced after two weeks of MOPL30 intake
(23.3%), and remained unchanged, however insignificantly,
one (34.3%, p = 0.17) and four weeks (29.8%, p = 0,24) after
discontinued supplementation (Figure 1b). Despite a high
PL content in the supplement, plasma PL levels were not
altered (Figure 1c).
The total cholesterol level in plasma was not changed by
MOPL30 intake (Figure 1d). HDL-cholesterol, however,
increased by 5.5% at end compared to start (Figure 1e),
while LDL-cholesterol was unchanged (Figure 1f). This
led to a trend towards an increased HDL/LDL-cholesterol
after MOPL30 intake (9.0%; Figure 1g). Surprisingly, while
plasma HDL-cholesterol returned to initial values after
four weeks of WO, total- and LDL-cholesterol was signifi-
cantly reduced at 4 week WO compared to start samples
(10.6% reduction in WO week 4 vs. start).
Fatty acid composition in plasma and red blood cells
Total fatty acid composition was measured in plasma
before and after two weeks of supplement. Total n-3
PUFAs in plasma were increased 1.6 fold, mainly due to
a 2.2 fold increase in EPA, and a 1.5 fold increase in
DHA (Table 1). One week after the end of supplementa-
tion, EPA and DHA had decreased by 44% and 24%, re-
spectively, compared to the end values. By four weeks of
WO, all plasma n-3 PUFAs had returned to start levels.
Concomitant with the increase in EPA and DHA during
the 2 weeks supplementation, n-6 PUFAs showed a de-
crease of 8.2%. Interestingly, n-6 PUFAs, in particular
arachidonic acid (AA) did not return to start levels
as quickly as EPA and DHA after discontinuation of
supplementation.
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Figure 1 Plasma lipid levels in response to MOPL30. Levels of triacylglycerol (TAG, a), non-esterified fatty acids (NEFA, b), phospholipids (c),
total cholesterol (d), high-density lipoprotein (HDL) cholesterol (e), low-density lipoprotein (LDL) cholesterol (f), and the HDL/LDL cholesterol ratio
(g) in fasted plasma samples taken at baseline (start), after 14 days of supplement (end), and one week (wash out (WO) week 1) and four weeks
(WO week 4) after discontinuation of supplement. Values are given as means with standard deviations, and significant changes between start and
end (n = 21) and start and WO (n = 13) are indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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week WO samples. Although mead acid was low in start
samples, as expected with a high habitual PUFA intake, it
still showed a significant decrease with the MOPL30 sup-
plement (27.7% reduction). The total fatty acid content in
plasma was significantly reduced after two weeks of supple-
ment, consistent with the reduced TAG and NEFA. The n-
6/n-3 PUFA ratio was within recommendations in the start
samples, consistent with the participants’ balanced intake
of fatty acids (Table 1). The n-6/n-3 ratio was further de-
creased by 44.8% post-supplementation, but had returned
to start values at WO week 4.
As most of the EPA and DHA in MOPL30 are in the
form of PC, the fatty acid composition of PC was mea-
sured both in plasma and in red blood cells. The findings
in plasma PC paralleled the findings in total plasma FAs,
with a 2.1 fold increase in EPA and a 1.6 increase in DHA
post-supplementation, resulting in a 45.2% decrease in the
n-6/n-3 PUFA ratio (Table 2). At WO week 1, EPA and
DHA were reduced by 39.3% and 21.9%, respectively, rela-
tive to end values. Incorporation of EPA and DHA into
RBC membranes is believed to better indicate long term
storage than plasma levels [12]. We found a 2.1 fold
increase in EPA and a 1.4 fold increase in DHA post-
supplement, similar to results in plasma, resulting in a 1.7
fold increase in the RBC PC omega-3 index and a 40.6%
reduction in the n-6/n-3 PUFA ratio (Table 3). AA in the
plasma PC and RBC PC was not significantly altered byMOPL30, although it was significantly reduced in plasma
total fatty acids (Tables 1, 2 and 3). The WO effect on the
RBC PC EPA was similar to that in the plasma PC after
one week (39% reduction relative to end values), while the
decrease in the RBC PC DHA was lower (11% reduction
relative to end values).Plasma choline increased with MOPL30
Both choline and its metabolite betaine increased in
plasma after two weeks of MOPL30 supplement (Figure 2).
Although the intake of PC was increased during supple-
mentation, total plasma- and RBC PCs were reduced post-
supplementation, as measured by 31P nuclear magnetic
resonance (NMR) (Figure 3a and b). However, a higher
proportion of EPA and DHA-containing PCs were ob-
served in both plasma and RBC (Tables 2 and 3). Plasma
TAG was reduced, while no change was seen in choles-
terol esters (Figure 3a). Total cholesterol, measured by 1H
NMR, was not influenced by two weeks of supplement
(mean ± SD start vs end; 0.95 ± 0.18 mmol/L vs 0.88 ±
0.019 mmol/L, p = 0.096). The plasma TAG level mea-
sured with NMR was similar to the plasma TAG-level
measured by enzymatic-analysis (Figure 1). Sphingomyelin
(SPH), PC, and cholesterol were reduced in RBC by two
weeks of MOPL30 treatment (Figure 3b). Interestingly,
while cholesterol returned to start levels after four weeks
WO, SPH and PC remained lower than start values.
Table 1 Plasma fatty acids during the study
μg FA/ml plasma Start End WO 1 week WO 4 weeks
∑ FAs 2999 ± 605 2811 ± 449* 2767 ± 409* 2677 ± 443**
∑ SFAs 956.4 ± 219.2 881.5 ± 151.1* 875.4 ± 154.8 708.6 ± 207.1**
C16:0 651.9 ± 172.0 589.5 ± 121.6** 582.0 ± 119.6 558.2 ± 121.6**
∑ MUFAs 708.6 ± 207.1 573.8 ± 124.8*** 613.4 ± 132.7* 583.4 ± 140.5*
C16:1n-7 39.8 ± 19.2 30.8 ± 11.6* 34.6 ± 20.3 34.1 ± 17.6
C16:1n-9 6.91 ± 2.85 6.10 ± 2.08* 6.63 ± 2.80 6.90 ± 2.75*
C18:1n-7 45.2 ± 15.4 36.5 ± 10.6** 36.1 ± 6.6* 36.4 ± 9.3
C18:1n-9 568.2 ± 171.9 454.0 ± 101.0*** 491.9 ± 112.1* 463.4 ± 111.1*
∑ n-9 PUFAs 3.10 ± 1.29 2.24 ± 0.48** 2.75 ± 1.38 2.55 ± 1.01**
C20:3n-9 (MA) 3.10 ± 1.29 2.24 ± 0.48** 2.75 ± 1.38 2.55 ± 1.01**
∑ n-6 PUFAs 1123 ± 190 1031 ± 180* 1036 ± 148* 1049 ± 141*
C18:2n-6 862.7 ± 147.9 806.2 ± 153.3 814.5 ± 110.1 821.0 ± 93.7
C20:2n-6 6.26 ± 2.43 4.91 ± 1.76*** 5.52 ± 1.64 5.90 ± 2.08
C18:3n-6 7.75 ± 5.00 4.33 ± 2.41*** 6.96 ± 4.075 7.16 ± 6.84
C20:3n-6 40.5 ± 17.3 27.7 ± 9.93*** 33.3 ± 9.78* 35.4 ± 13.9
C20:4n-6 (AA) 197.8 ± 51.6 182.3 ± 41.1* 170.3 ± 41.6*** 173.0 ± 50.9*
C22:4n-6 4.33 ± 1.58 2.92 ± 0.71*** 3.32 ± 0.92** 3.70 ± 1.56**
∑ n-3 PUFAs 200.8 ± 64.1 315.6 ± 62.8*** 232.7 ± 62.9 197.0 ± 74.0
C18:3n-3 19.8 ± 8.17 16.6 ± 6.06* 20.0 ± 8.85 19.0 ± 8.0
C20:5n-3 (EPA) 49.4 ± 27.1 109.7 ± 37.1*** 61.7 ± 31.7 47.3 ± 32.7
C22:5n-3 (DPA) 17.6 ± 5.36 18.4 ± 4.27 18.0 ± 4.22 17.0 ± 5.43
C22:6n-3 (DHA) 108.1 ± 30.4 166.1 ± 30.5*** 127.0 ± 29.5** 108.4 ± 35.2
∑ n-6:∑ n-3 ratio 6.10 ± 1.81 3.37 ± 0.82*** 4.75 ± 1.42* 5.88 ± 1.72
Abbreviations: AA arachidonic acid, DHA docosahexaenoic acid; EPA eicosapentaenoic acid; FA fatty acid; MA mead acid; MUFA unsaturated fatty acids;
PUFA polyunsaturated fatty acids; SFA saturated fatty acids; WO, wash out.
Data are means ± SD. Significantly different end and start values (n = 21) and WO and start values (n = 13) are indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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Carnitine is essential in the transport of long-chain
fatty acids across the mitochondrial membranes. High
serum levels of long- and medium-chain plasma acyl-
carnitines are linked to increased risk of disease pro-
gression in patients with cardiac disease, and may
indicate defects in mitochondrial function [13]. In the
current study with healthy individuals, carnitine was
insignificantly reduced (p = 0.054), while its precursors
γ-butyrobetaine and trimethyllysine were reduced by
MOPL30 (Figure 4a-c). In addition, all measured plasma
acylcarnitines except the medium-chain octanoylcarni-
tine (8-carbon, p = 0.103), were significantly reduced by
MOPL30 (Figure 4d-h). The largest reduction (29% com-
pared to start) was seen for the short-chain acetylcarnitine
(2-carbon). The effect on γ-butyrobetaine, trimethyllysine
and all acylcarnitines remained significantly reduced com-
pared to start in both the one- and four week WO samples,
indicating a possible prolonged effect of the supplement on
these parameters.Oral glucose tolerance test
Since previous studies in animals have indicated improved
glucose metabolism after herring roe diets, we investigated
the effect of two weeks MOPL30 supplement on glucose
tolerance in healthy individuals. No change was observed
in fasting insulin and glucose before and after the supple-
mentation period (Figure 5a and b). However, the blood
glucose level in response to a 75 g oral dose of glucose
was reduced both at 10 and 120 minutes post-ingestion
after the intervention (Figure 5c). Although all participants
were individuals with normal glucose sensitivity according
to their glucose tolerance test results, the area under the
curve was significantly decreased, suggesting improved
glucose response (Figure 5d).
Discussion
There is an increased demand for new sources of high-
quality n-3 PUFAs for human consumption, and PC-rich
lipids from herring roe is a promising product in this re-
gard. Supplementation with DHA- and EPA-rich PC may
Table 2 Plasma phosphatidylcholine fatty acids during the study
Fatty acids, wt% Start End WO 1 week WO 4 weeks
C16:0 27.1 ± 3.11 26.8 ± 3.07 26.6 ± 3.73 27.2 ± 3.54
C16:1n-7 0.48 ± 0.14 0.46 ± 0.10 0.48 ± 0.25 0.79 ± 0.82
C18:1n-7 1.54 ± 0.20 1.52 ± 0.25 1.50 ± 0.25 1.41 ± 0.24
C18:1n-9 10.8 ± 1.66 9.60 ± 1.14** 10.9 ± 1.92 10.6 ± 2.03
C20:3n-9 (MA) 0.12 ± 0.04 0.08 ± 0.02*** 0.11 ± 0.06 0.11 ± 0.04*
C18:2n-6 23.8 ± 2.73 21.9 ± 2.75* 23.6 ± 2.16 24.2 ± 3.02
C20:2n-6 0.53 ± 0.10 0.47 ± 0.07*** 0.50 ± 0.10 0.51 ± 0.10
C20:3n-6 2.58 ± 0.78 1.87 ± 0.55*** 2.26 ± 0.54 2.43 ± 0.68
C20:4n-6 (AA) 8.07 ± 1.31 7.65 ± 1.34 7.16 ± 1.49* 7.34 ± 1.53
C22:4n-6 0.26 ± 0.20 0.17 ± 0.03* 0.18 ± 0.04** 0.20 ± 0.07
C18:3n-3 0.25 ± 0.08 0.20 ± 0.06** 0.30 ± 0.15 0.30 ± 0.02
C20:5n-3 (EPA) 1.90 ± 1.01 3.97 ± 1.43*** 2.41 ± 1.30 1.84 ± 1.02
C22:5n-3 (DPA) 0.77 ± 0.17 0.85 ± 0.20 0.82 ± 0.17 0.76 ± 0.15
C22:6n-3 (DHA) 4.20 ± 0.87 6.52 ± 1.10*** 5.09 ± 1.03** 4.25 ± 0.67
∑ n-6:∑ n-3 ratio 5.29 ± 1.41 2.90 ± 0.68*** 4.15 ± 1.13 5.12 ± 1.23
Abbreviations: AA arachidonic acid, DHA docosahexaenoic acid; EPA eicosapentaenoic acid; FA fatty acid; MA mead acid; MUFA unsaturated fatty acids;
PUFA polyunsaturated fatty acids; SFA saturated fatty acids; WO wash out.
Data are means ± SD. Significantly different end and start values (n = 21) and WO and start values (n = 13) are indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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TAG both due to PL being more easily incorporated
into cellular membranes, as well as being a source of
the essential nutrient choline. In this two-week inter-
vention in young healthy adults with high habitual fish
intakes, there was a rapid increase in EPA and DHA in
RBC PC, plasma FA and plasma PC. Furthermore, thereTable 3 Red blood cell phosphatidylcholine fatty acids during
Fatty acids, wt% Start En
C16:0 32.2 ± 3.62 31.3 ±
C16:1n-7 0.33 ± 0.15 0.24 ± 0
C18:1n-7 1.65 ± 0.19 1.67 ±
C18:1n-9 16.2 ± 1.53 15.8 ±
C20:3n-9 (MA) 0.06 ± 0.02 0.05 ±
C18:2n-6 20.0 ± 1.65 18.8 ± 1
C20:2n-6 0.32 ± 0.10 0.34 ±
C20:3n-6 1.65 ± 0.06 1.34 ± 0
C20:4n-6 (AA) 5.33 ± 0.90 5.18 ±
C22:4n-6 0.22 ± 0.09 0.22 ±
C18:3n-3 0.18 ± 0.07 0.23 ±
C20:5n-3 (EPA) 1.10 ± 0.47 2.35 ± 0
C22:5n-3 0.53 ± 0.10 0.56 ±
C22:6n-3 (DHA) 2.43 ± 0.52 3.48 ± 0
∑ n-6:∑ n-3 ratio 6.85 ± 1.64 4.07 ± 0
Omega-3 index 3.53 ± 0.88 5.83 ± 1
Abbreviations: AA arachidonic acid, DHA docosahexaenoic acid; EPA eicosapentaeno
PUFA polyunsaturated fatty acids; SFA saturated fatty acids; WO wash out.
Data are means ± SD. Significantly different end and start values (n = 21) and WO awas a corresponding improved lipid status, including a
decrease in plasma TAG and NEFA, and increased HDL-
cholesterol, choline, and betaine. These findings demon-
strate that MOPL30 had significant biological effects in
healthy subjects.
The participants were given 2350 mg EPA and DHA
daily, comparable to doses utilized in patients with CVDthe study
d WO 1 week WO 4 weeks
3.43 31.6 ± 3.46 31.6 ± 3.87
.05** 0.30 ± 0.14 0.29 ± 0.12
0.18 1.60 ± 0.17 1.62 ± 0.15
0.98* 16.1 ± 1.00 15.8 ± 1.20
0.02 0.05 ± 0.02* 0.05 ± 0.02
.80*** 20.2 ± 1.55 20.96 ± 1.83
0.06 0.32 ± 0.05 0.34 ± 0.07
.38*** 1.35 ± 0.32*** 1.49 ± 0.39
0.86 4.97 ± 0.91* 4.48 ± 1.48
0.06 0.23 ± 0.04 0.21 ± 0.07
0.28 0.18 ± 0.07 0.17 ± 0.05
.85*** 1.43 ± 0.57 1.08 ± 0.54
0.13 0.56 ± 0.11 0.55 ± 0.11
.60*** 3.10 ± 0.63** 2.58 ± 0.52
.80*** 5.37 ± 1.12** 6.58 ± 1.40
.26*** 4.52 ± 0.94* 3.65 ± 0.84
ic acid; FA fatty acid; MA mead acid; MUFA unsaturated fatty acids;
nd start values (n = 13) are indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 2 Plasma choline and betaine levels in response to MOPL30. Levels of choline (a) and betaine (b) in fasted plasma samples taken at
baseline (start), after 14 days of supplement (end), and one week (wash out (WO) week 1) and four weeks (WO week 4) after discontinuation of
supplement. Values are given as means with standard deviations, and significant changes between start and end (n = 21) and start and WO
(n = 13) are indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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http://www.lipidworld.com/content/13/1/82or metabolic syndrome to achieve a TAG-lowering effect.
In line with this, plasma TAG was reduced and HDL-
cholesterol increased after only two weeks of treatment.
This indicates a high bioavailability of MOPL30 and a sub-
sequent rapid effect on lipid metabolism. It has been shown
that the preferred lipid form for transport of DHA to RBC
is lyso-PC, which is rapidly converted to PC [14,15]. This
could mean that DHA-rich PC may be preferred for uptake
in RBC and putatively in brain. Incorporation of EPA from
fish oil into RBC membranes has been shown to reach a
steady state after 180 days [12]. Notably, we observed an in-
crease in EPA and DHA in RBC PC similar to that of
plasma after only 14 days. In mice, we recently showed that
similar amounts of EPA and DHA in liver PL were achieved
with krill oil and a two-fold higher dose of EPA and DHA
from fish oil, indicating higher bioavailability of EPA and
DHA from the PL-source krill oil [16]. Importantly, in aPlasma lipid classes
SP
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Figure 3 Lipid classes in plasma and red blood cells (RBC) in respons
triacylglycerol (TAG), phosphatidyl ethanolamine (PE), lysophosphatidyletha
at baseline (start) and after 14 days of supplement (end) in fasting plasma
(Chol.) at start, end, and one week (wash out (WO) week 1) and four weeks
was done by 31P NMR. Values are given as means (%w/w = g/100 g plasma
end (n = 21) and start and WO (n = 13) are indicated (*p < 0.05, **p < 0.01).recent study in which subjects were supplemented with
600 mg EPA and DHA from either fish- or krill oil, the
omega-3 index was significantly higher in subjects receiving
krill oil than in those given fish oil [8]. However, no effect
on plasma TAG was observed at 600 mg/day EPA + DHA.
A recent study in adults with high TAG levels showed that
a dose of 0.5-2 g/day krill oil for 12 weeks significantly re-
duced TAG [17].
Although the intake of DHA exceeded that of EPA by
2.8 fold, the increase in EPA was higher than DHA in the
PC-fraction of both plasma and red blood cells after two
weeks of MOPL30. Studies have shown that the DHA
level in lipid pools has a less steep dose–response curve
than EPA, which is easy to influence by supplementation
[18], and our results confirm this. This can partly be due
to more efficient liberation of DHA from chylomicrons
[19], leaving more EPA in chylomicron remnants andRBC lipid classes
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In addition, retro-conversion of DHA to EPA is dependent
on peroxisomal β-oxidation, and is reported to be at ap-
proximately 10% in humans [20,21]. Hansen et al. showed
that 4 g supplement of pure EPA for 5 weeks led to a 6.2
fold increase in EPA in plasma phospholipids, and no
change in DHA [18]. In contrast, the same intervention
using a pure DHA supplement led to a 1.9 fold increase in
DHA and a 1.7 fold increase in EPA. This demonstrates the
importance of supplementation with DHA and not onlyEPA. Despite a dose of 132 mg DPA/day, and the possibility
of formation of DPA from EPA, DPA levels were not influ-
enced by two weeks of MOPL30. In line with this, a de-
crease in DPA after uptake of EPA or DHA has been
reported in long-term studies [22,23].
Indications of differential effects of n-3 PUFA in PL
and TAG form have also been found at the gene level in
several animal studies [6,7], including genes involved in
glucose metabolism. A recent study reported that EPA
and DHA supplements may improve insulin sensitivity
Fasting glucose
m
m
o
l/L
Sta
rt
En
d
WO
 we
ek 
1
WO
 we
ek 
4
0
2
4
6
Oral glucose tolerance test
0 30 60 90 120 150
0
2
4
6
8
10
Time (min)
m
m
o
l/L
Start
End
* *
Fasting insulin
m
IU
/L
Sta
rt
En
d
WO
 we
ek 
1
WO
 we
ek 
4
0
2
4
6
8
10
Area under the curve (AUC)
Sta
rt
En
d
500
600
700
800
900
1000
m
in
*
m
m
o
l/L *
a b
c d
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have failed to show an effect between n-3 PUFA intake and
incident type 2 diabetes mellitus (T2DM) [25,26], others in-
dicate a reduced risk of T2DM with increased intake of
PUFAs [27,28]. Based on findings in humans and from re-
cent animal studies, PL supplements could be expected to
have potent effects on glucose metabolism. The small, but
significant, improvement in glucose response in healthy in-
dividuals after only two weeks of intervention suggests a
potential for the use of MOPL30 in insulin resistant indi-
viduals, or patients with diabetes.
The conditionally essential nutrient choline is a quater-
nary amine, and is mainly utilized for the synthesis of PC
and sphingomyelin, as well as lysophosphatidylcholine. In
addition, choline can be oxidized to betaine, which is in-
volved in the remethylation of homocysteine to methio-
nine in the one-carbon cycle [29]. Finally, in the neurons
choline is a precursor for the important neurotransmittor
and vasodilator acetylcholine [30-32], and increased intake
has been connected with improved cognition, learning
and memory [33-35]. Betaine holds an important role in
the liver, and has a potential therapeutic use in thetreatment of fatty liver disease as well as homocysteine-
mia, a risk factor for CVD [36,37]. In addition, some
studies have demonstrated that betaine supplements
improve muscle performance [38]. PC biosynthesis is
required for VLDL production, both through the CDP-
choline (Kennedy) pathway and the phosphatidyletha-
nolamine N-methyltransferase (PEMT) pathway. In general,
a balanced diet will provide sufficient amounts of choline,
but groups which may benefit from choline supplementa-
tion are pregnant and lactating women, infants, and cirrho-
sis patients [39]. Thus, a PC supplement can both reduce
the need for methyl-donors for PC synthesis, and supply
betaine for homocysteine remethylation, which will be
beneficial in situations where methyl donors are limited
[40]. Interestingly, while MOPL30 supplementation led to
increased EPA and DHA-rich PC in plasma and RBC, the
total level of PC decreased, with a concomitant increase in
plasma free choline. This may indicate a higher level of
PC degradation as a result of increased dietary intake, en-
suring maintenance of the strictly regulated choline bal-
ance in the human body [41]. We were unable to measure
acetylcholine in plasma due to its short half-life, however,
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production of acetylcholine may potentially have been
stimulated by increased choline levels. DHA has been
demonstrated to increase synaptic transmission in mam-
malian brain cells, and this effect was potentiated by phos-
phatidylcholine [42]. Thus, MOPL30 may have beneficial
effects on cognitive function. It would be valuable to
measure plasma choline acetyltransferase activity in future
clinical trials to verify if acetylcholine production is stimu-
lated by MOPL30 in humans.
As high plasma levels of long- and medium-chain
acylcarnitines are linked to increased heart failure in
CVD patients, they have been put forward as potential
biomarkers of cardiovascular risk [13]. Incomplete β-
oxidation, impaired substrate switching, and dysregula-
tion of mitochondria during insulin resistance can cause
elevated levels of intermediate oxidation products, and
this can be reflected in plasma acylcarnitine levels [43,44].
Thus, it is of interest to establish whether dietary interven-
tion with n-3 PUFAs affect these plasma parameters in
healthy adults, as EPA and DHA are known to stimulate
mitochondrial β-oxidation. We observed a reduction in all
acylcarnitines after a two-week intervention with MOPL30,
including the risk-associated palmitoylcarnitine.
In further studies it will be interesting to determine if the
supplement can benefit patients with insulin resistance,
both with regard to plasmaTAG levels, mitochondrial func-
tion, and glucose tolerance. It will be of particular interest
to compare the bioactivity of MOPL30 and TAG EPA and
DHA supplements at lower doses of EPA and DHA. In
a follow-up study, a double blind comparison to fish oil
will be performed to identify possible PL-specific effects of
MOPL30. Also, a rodent study is planned to examine
bioaccretion of EPA and DHA into brain and other tissues.
Conclusions
EPA and DHA-rich PC from herring roe was taken up by
RBC during the two week intervention. Several parameters
in blood were affected, including a reduction in TAG and
NEFA, and an increase in HDL cholesterol, choline, and
betaine. Further, there was improved glucose tolerance
among the participants after two weeks. Based on the
findings from this short-term pilot study with 2.4 g EPA +
DHA per day, MOPL30 may provide significant effects on
lipid status and glucose tolerance.
Methods
Study subjects
This intervention study was performed at the University
of Bergen according to Good Clinical Practice Guidelines
and the World Medical Association Declaration of
Helsinki. The Regional Ethics Committee, REK vest, ap-
proved the protocol (REK vest, approval no. 2013/112),
and informed consent was obtained from all the subjects.Healthy young adults (21 women and one man) aged
21 to 26 years were recruited on a voluntary basis. Of
the 27 adults asked, six were not included in the study
due to unwillingness to take capsules and/or blood sam-
ples. Exclusion criteria were conditions requiring medica-
tion, pregnancy and diabetes type I or II. The participants
were instructed not to make any major changes to their
diet three weeks before, during, or four weeks after inter-
vention, with the exception of avoiding using fish egg
products like caviar. Participants were instructed to per-
form a three-day weighed food record within the two
weeks before, as well as during the intervention. Results
were analyzed by the program “Mat på Data” (http://www.
matportalen.no/verktoy/mat_pa_data/), and mean dietary
intake of nutrients of interest were calculated as percent-
age of total energy intake (energy %).
Supplement and study design
MOPL30 is a capsulated herring roe PL supplement,
where each capsule contains 511 mg total lipid, of which
30% are PL, with 56 mg EPA, 158 mg DHA, and 12 mg n-
3 DPA. The participants received 11 capsules per day for
14 days, corresponding to a daily dose of 1738 mg DHA
and 616 mg EPA. Four capsules were taken at breakfast
and lunch and three capsules were taken at dinnertime.
The last day of capsule intake (end), blood samples were
drawn the next morning between 8 and 11 am after an
overnight fast, an oral glucose tolerance test was per-
formed (see description below), and capsules were divided
between the remaining meals of the day. Blood samples
were drawn the next morning after taking the last capsule
between 8 and 11 am after an overnight fast, followed by
an oral glucose tolerance test. Of the 21 participants, 14
were recruited for additional fasting blood samples one
week (WO week one) and four weeks (WO week four)
after the final day of supplement. One participant was ex-
cluded due to lack of fasting at WO week four. All blood
samples were centrifuged and EDTA-plasma and serum
was separated after a minimum of 15 minutes and max-
imum of 30 minutes at room temperature. Blood samples
for isolation of RBC were drawn in EDTA tubes, centri-
fuged at 3000 rpm for 10 minutes, and plasma and inter-
face removed. RBC were subsequently washed three times
in PBS, with centrifugation and removal of buffy coat be-
tween each wash. All samples were aliquoted and stored
at −80°C for further analysis.
Oral glucose tolerance test
After an overnight fast, blood was drawn for measurement
of fasting glucose and insulin as described above. In
addition, a rapid analysis of blood glucose was performed
using a FreeStyle Lite (Abbott Diabetes Care, Inc., Alameda,
CA, USA). Glucose dissolved in water was ingested in no
more than 5 minutes (300 ml 0.25 g/ml glucose with 5%
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http://www.lipidworld.com/content/13/1/82lemon juice), and blood glucose was measured by FreeStyle
Lite at 10, 30, 60 and 120 minutes after glucose ingestion.
The area under the curve was calculated by Prism Graph-
Pad Software (San Diego, CA, USA).
Enzymatic analysis of blood parameters
Lipids were measured enzymatically in EDTA plasma on a
Hitachi 917 system (Roche Diagnostics GmbH, Mannheim,
Germany) using the triacylglycerol (GPO-PAP), cholesterol
(CHOD-PAP), HDL-cholesterol plus and LDL-cholesterol
plus kit from Roche Diagnostics, and the non-esterified
fatty acid (NEFA FS) kit and the Phospholipids FS kit from
DiaSys Diagnostic Systems GmbH (Holzheim, Germany).
Glucose was measured in EDTA-plasma using the Gluco-
quant Glucose/HK (GLU) kit from Roche Diagnostics. In-
sulin was measured using routine methods at the central
laboratory at Haukeland University Hospital.
Analysis of plasma total fatty acid composition, and
plasma and RBC PC fatty acid composition
The total fatty acid composition in EDTA-plasma was an-
alyzed as previously described [45]. For analysis of the
plasma PC fatty acids, plasma total lipids were extracted
based on Folch, then PC was separated from other lipids
by HPLC using YMC diol-120-NP column, 250 mm×
4.6 mm ID, using hexane/acetone/methanol/chloroform
(1/1/6/4) as the eluting solvent system. The column efflu-
ent was spilt to an evaporative light scattering detector for
quantitation and to fraction collector for recovery. Fatty
acids in the PC fraction were converted to their respective
methyl esters then separated and quantified by capillary
column GLC [46].
Analysis of plasma and RBC lipid composition by 1H
or 31P NMR
Lipids were extracted from 0.5 ml serum by Folch Solvent
(1 ml each of CDCl3 MeOD and CsEDTA (0.2 M), pH 8).
After centrifugation, the lower layer was analyzed at
600 MHz cQNP using a NMR spectrometer Avance III
600 (Bruker, Karlsruhe, D), magnetic flux density 14.1
Tesla, a QNP cryo probe, and automated sample changer
Bruker B-ACS 120. Computer Intel Core2 Duo 2.4 GHz
under MS Windows XP and Bruker TopSpin 2.1 was used
for acquisition, while Bruker TopSpin 2.1 was used for
processing [47-50].
Plasma choline, betaine, carnitine and acylcarnitines
Plasma choline, betaine, free carnitine and its precur-
sors: trimethyllysine and γ-butyrobetaine, as well as short-,
medium-, and long-chain acylcarnitines, were analysed in
plasma using LC/MS/MS as described previously [10].
Stable isotope dilution LC/MS/MS was used for quantifi-
cation of choline and betaine. Choline and betaine were
monitored in positive MRM MS mode using characteristicprecursor-product ion transitions: m/z 76→ 58, m/z
104→ 60 and m/z 118→ 58, respectively. The internal
standards, choline-trimethyl-d9 (d9-choline) and d11-
betaine, were added to plasma samples before protein pre-
cipitation, and were similarly monitored in MRM mode at
m/z 85→ 66, m/z 113→ 69 and m/z 129→ 66, respect-
ively. Various concentrations of choline and betaine stan-
dards and a fixed amount of internal standards were spiked
into 4% albumin (BSA) to prepare the calibration curves for
quantification of plasma analytes.
Statistical analysis
Data was analyzed using Prism Software (Graph-Pad Soft-
ware). The results are shown as means with standard devi-
ation (SD). D’Agostino & Pearson omnibus normality test
was used to determine normal distribution. Paired t-test or
Wilcoxon matched-pairs signed ranked test, for parametric
data and non-parametric data, respectively, were per-
formed to evaluate statistical differences between start and
end samples, between end and WO week one, and between
end and WO week four samples. P-values < 0.05 were con-
sidered significant.
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